Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
| Autor: | Amanda McIver, Ken Jiang, Jagoda Jasielec, Andrzej Jakubowiak, Andrew T. Stefka, Benjamin A. Derman, Tadeusz Kubicki |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Myeloma Hematology Disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease lcsh:RC254-282 Carfilzomib Phase II trials Peripheral blood chemistry.chemical_compound Autologous stem-cell transplantation chemistry Internal medicine Correspondence medicine business Dexamethasone Multiple myeloma medicine.drug Lenalidomide |
| Zdroj: | Blood Cancer Journal, Vol 11, Iss 2, Pp 1-4 (2021) Blood Cancer Journal |
| ISSN: | 2044-5385 |
| DOI: | 10.1038/s41408-021-00418-2 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink